Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

NCT01955499 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01955499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01955499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 24, 2013
Completion date
May 6, 2027
Enrollment
39 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent lymphoplasmacytic lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory lymphoplasmacytic lymphoma, refractory mantle cell lymphoma, refractory marginal zone lymphoma